Oculis Holding AG (NASDAQ:OCS) Sees Significant Decline in Short Interest

Oculis Holding AG (NASDAQ:OCS) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 25,000 shares, a decline of 14.1% from the February 13th total of 29,100 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average trading volume of 71,300 shares, the short-interest ratio is presently 0.4 days.

Institutional Trading of Oculis

Several institutional investors have recently made changes to their positions in the stock. Bellevue Group AG purchased a new position in shares of Oculis in the 4th quarter worth $170,000. XTX Topco Ltd acquired a new stake in Oculis during the fourth quarter worth about $225,000. Geode Capital Management LLC increased its stake in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock worth $284,000 after acquiring an additional 1,800 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Oculis during the fourth quarter worth about $389,000. Finally, Bank of America Corp DE increased its stake in Oculis by 58.2% during the fourth quarter. Bank of America Corp DE now owns 28,980 shares of the company’s stock worth $493,000 after acquiring an additional 10,667 shares during the last quarter. 22.30% of the stock is owned by hedge funds and other institutional investors.

Oculis Trading Up 2.4 %

Oculis stock traded up $0.46 during trading on Thursday, hitting $19.20. The company’s stock had a trading volume of 25,094 shares, compared to its average volume of 45,536. The stock’s fifty day moving average is $20.96 and its 200 day moving average is $17.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. Oculis has a 1-year low of $10.55 and a 1-year high of $23.08. The stock has a market capitalization of $838.09 million, a price-to-earnings ratio of -9.95 and a beta of 0.01.

Oculis (NASDAQ:OCS) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.28). Oculis had a negative net margin of 8,043.28% and a negative return on equity of 71.31%. As a group, equities research analysts predict that Oculis will post -2.09 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $28.00 price target on shares of Oculis in a research report on Thursday, March 13th. HC Wainwright dropped their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research report on Thursday, March 13th. Finally, Robert W. Baird upped their price objective on Oculis from $37.00 to $41.00 and gave the company an “outperform” rating in a research report on Thursday, March 13th.

Oculis Company Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.